Evidence map›Paper›PMID 38710213›Full record

ArticleCancer science2024

Circular RNA circESYT2 serves as a microRNA-665 sponge to promote the progression of hepatocellular carcinoma through ENO2.

Wei Du, Ying Li, Xufeng Wang, Sunzhe Xie, Hongfei Ci, Jiaming Zhou, Ningqi Zhu, Zule Chen, Yan Zheng, Huliang Jia

Abstract read
In one paragraph

Article in Cancer science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. H4K5 lactylation - ENO2 loop drives glycolysis and HCC progression.JHEP reports : innovation in hepatology · 2026
    Article
  2. Role of Circular RNAs in Liver Diseases.International journal of medical sciences · 2026
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wei DuHepatobiliary Surgery, Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China.
Ying LiHepatobiliary Surgery, Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China.
Xufeng WangHepatobiliary Surgery, Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China.
Sunzhe XieHepatobiliary Surgery, Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China.
Hongfei CiHepatobiliary Surgery, Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China.
Jiaming ZhouHepatobiliary Surgery, Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China.
Ningqi ZhuHepatobiliary Surgery, Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China.
Zule ChenHepatobiliary Surgery, Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China.
Yan ZhengDepartment of Pancreatic Surgery, Shanghai General Hospital, Shanghai Key Laboratory of Pancreatic Disease, Institute of Pancreatic Disease, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Huliang JiaHepatobiliary Surgery, Department of General Surgery, Huashan Hospital, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0002-9782-123X

Funding

National Natural Science Foundation of China 8187110643
6 · The paper itself

Abstract

Circular RNAs (circRNAs) have emerged as crucial regulators in tumor progression, yet their specific role in hepatocellular carcinoma (HCC) remains largely uncharacterized. In this study, we utilized high-transcriptome sequencing to identify the upregulation of circESYT2 (hsa_circ_002142) in HCC tissues. Functional experiments carried out in vivo and in vitro revealed that circESYT2 played a significant role in maintaining the growth and metastatic behaviors of HCC. Through integrative analysis, we identified enolase 2 (ENO2) as a potential target regulated by circESYT2 through the competitive endogenous RNA sponge mechanism. Additional gain- or loss-of-function experiments indicated that overexpression of circESYT2 led to a tumor-promoting effect, which could be reversed by transfection of microRNA-665 (miR-665) mimic or ENO2 knockdown in HCC cells. Furthermore, the direct interaction between miR-665 and circESYT2 and between miR-665 and ENO2 was confirmed using RNA immunoprecipitation, FISH, RNA pull-down, and dual-luciferase reporter assays, highlighting the involvement of the circESYT2/miR-665/ENO2 axis in promoting HCC progression. These findings shed light on the molecular characteristics of circESYT2 in HCC tissues and suggest its potential as a biomarker or therapeutic target for HCC treatment.

Indexed as

Carcinoma, HepatocellularDisease ProgressionGene Expression Regulation, NeoplasticLiver NeoplasmsMicroRNAsPhosphopyruvate HydrataseRNA, CircularAnimalsCell Line, TumorCell ProliferationDNA-Binding ProteinsFemaleHumansMaleMiceMice, NudeDNA-Binding ProteinsENO2 protein, humanESYT2 protein, humanMicroRNAsMIRN665 microRNA, humanPhosphopyruvate HydrataseRNA, CircularSynaptotagminsceRNAcircESYT2ENO2hepatocellular carcinoma progressionmiR‐665

Identifiers

PMID38710213
PMCPMC11309938

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.